Search results for "38"
showing 10 items of 1730 documents
STUDIO DELLA FUNZIONALITA’ TIROIDEA NELL’INSUFFICIENZA RENALE CRONICA LIEVE-MODERATA: CASISTICA PEDIATRICA
2010
IPEREOSINOFILIA IN MALATTIA DI KAWASAKI: INDICE DI RISCHIO DI PATOLOGIA CARDIACA IN UNA CASISTICA PEDIATRICA SICILIANA
2019
La malattia di Kawasaki (MK) è una vasculite sistemica con possibile coinvolgimento cardiaco, coronarite e/o aneurismi coronarici (CAL), la cui diagnosi talora è resa complessa specie in forme atipiche e/o incomplete. Alcuni autori evidenziano il rilievo di eosinofilia >350/mm3, soprattutto in pazienti con resistenza alla terapia con immunoglobuline (IVIG). Infiltrato eosinofilo è stato documentato, inoltre, nelle coronarie di pazienti con CAL. Nel periodo 2015 -2018, presso la Clinica Pediatrica di Palermo, abbiamo studiato 17 bambini (13 M; 4 F; età: 5-146 mesi: Mediana: 24 mesi) con diagnosi di MK. 11/17 (65%; 8 M; 3 F) hanno avuto alterazioni cardiologiche; fra questi 7/11 (64%) con …
Efficacia di FK506 per uso topico e Infliximab nel trattamento del coinvolgimento cutaneo nelle malattie infiammatorie croniche intestinali.
2010
Neonatal osteomyelitis of the talus due to methicillin-resistant Staphylococcus epidermidis
2013
Acute osteomyelitis is a relatively rare disorder in the neonatal period, with considerable morbidity and mortality. Early diagnosis and prompt treatment are essential for a successful outcome. In this report we present a case of acute osteomyelitis of the talus due to methicillin-resistant Staphylococcus epidermidis, observed in a 30-day-old infant.
Propranolol and infantile hemangiomas: Outcome from a tricentric study.
2020
Introduction: The introduction of propranolol as systemic therapy for infantile hemangiomas (IH) has changed the natural history of these tumors. Cases presenting with ulceration, functional limitation, and visceral or life-threatening localization are excellent indications to medical therapy. The aim was to report the medium term follow-up after the introduction of propranolol in 3 referral centers with particular attention to outcome and surgical treatments. Materials and methods: In the period 2011-2018 348 patients underwent systemic therapy with propanolol at a mean age of 3.5 months (range 1-10). The indications to begin the treatment were: visceral localization (10,6%), ulceration (2…
Terapia con inibitori dell'IL-1 in pazienti con mutazioni di malattie autoinfiammatorie a bassa penetranza: una casistica dall'età pediatrica al giov…
2017
Iperinsulinismo congenito da mutazione in omozigosi di INS-R: descrizione di un caso
2014
L’ADOLESCENTE CON IPOGONADISMO IPOGONADOTROPO: LA CENTRALITA’ DEL RUOLO DEL PEDIATRA
2009
DEVELOPMENT AND INITIAL VALIDATION OF THE SYSTEMIC JADAS, A NEW COMPOSITE DISEASE ACTIVITY SCORE FOR SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
2019
Background: Juvenile Arthritis Disease Activity Score (JADAS) has gained increasing popularity for the measurement of the level of disease activity in patients with juvenile idiopathic arthritis (JIA). However, so far the JADAS has been validated only in children with the non-systemic categories of JIA. Objectives: To develop and validate the systemic JADAS (sJADAS), a new version of the JADAS specific to systemic JIA (sJIA). Methods: The sJADAS is made up by adding a fifth item, named Systemic Manifestation Score (SMS), to the four items included in the original tool (physician global assessment of disease activity, parent/patient global assessment of well-being, active joint count and ery…
ASSESSING THE CLINICAL RELEVANCE AND RISK MINIMIZATION OF ANTIBODIES TO BIOLOGICS IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) (ABIRISK) - PRELIMINARY RESU…
2018
Introduction: ABIRISK is a project funded by Innovative Medicine Initiative, with the aim to investigate anti-drug antibody (ADA) formation in the treatment of JIA with biologics (BPs). A major limitation to the use of biologics is the development of ADA that may decrease the efficacy of BPs. Objectives: The aim of this project is to improve the capability to predict biologic immunogenicity in JIA patients. Methods: JIA Patients (by ILAR criteria) followed by 24 PRINTO centres in 12 countries were prospectively enrolled and treated with Etanercept, Adalimumab or Tocilizumab. Patient’s data were obtained from Pharmachild, a pharmacovigilance data registry of JIA patients. For each patient de…